Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Ernest Borden

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Disorders

Living Beings

Mice

Activities & Behaviors

Drug Evaluation

Physiology

Cell Division

Anatomy

Procedures

Antineoplastic Combined Chemotherapy Protocols

Phenomena

Drug Synergism

Concepts & Ideas

Drug Administration Schedule

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
21
Lindner, Daniel
11
Schiller, Joan
10
Leaman, Douglas
9
Byrne, Gerald
8
Chawla-Sarkar, Mamta
7
Murphy, Frederick
7
Jacobs, Barbara
7
Kalvakolanu, Dhan
5
Yi, Taolin
5
Sondel, Paul
5
Paulnock, Donna
5
Ball, Andrew
4
Bae, Soo In
4
Guadagni, Fiorella
4
Greiner, John

Sign-in to see all Coauthors

Publications

TOP 3
Borden Ernest C; Kluger Harriet; Crowley John
Apoptosis: a clinical perspective.
Taylor Kevin L; Leaman Douglas W; Grane Ron; Mechti Nadir; Borden Ernest C; Lindner Daniel J
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.
Heinrich Michael C; Owzar Kouros; Corless Christopher L; Hollis Donna; Borden Ernest C; Fletcher Christopher D M; Ryan Christopher W; von Mehren Margaret; Blanke Charles D; Rankin Cathryn; Benjamin Robert S; Bramwell Vivien H; Demetri George D; Bertagnolli Monica M; Fletcher Jonathan A
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Ernest Borden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Borden Ernest C; Kluger Harriet; Crowley John
Apoptosis: a clinical perspective.
Nature reviews. Drug discovery 2008;7(12):959.
2008: Taylor Kevin L; Leaman Douglas W; Grane Ron; Mechti Nadir; Borden Ernest C; Lindner Daniel J
Identification of interferon-beta-stimulated genes that inhibit angiogenesis in vitro.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2008;28(12):733-40.
2008: Heinrich Michael C; Owzar Kouros; Corless Christopher L; Hollis Donna; Borden Ernest C; Fletcher Christopher D M; Ryan Christopher W; von Mehren Margaret; Blanke Charles D; Rankin Cathryn; Benjamin Robert S; Bramwell Vivien H; Demetri George D; Bertagnolli Monica M; Fletcher Jonathan A
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(33):5360-7.
2008: Kalmadi Sujith R; Rankin Cathryn; Kraut Michael J; Jacobs Andrew D; Petrylak Daniel P; Adelstein David J; Keohan Mary Louise; Taub Robert N; Borden Ernest C
Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810).
Lung cancer (Amsterdam, Netherlands) 2008;60(2):259-63.
2008: Blanke Charles D; Rankin Cathryn; Demetri George D; Ryan Christopher W; von Mehren Margaret; Benjamin Robert S; Raymond A Kevin; Bramwell Vivien H C; Baker Laurence H; Maki Robert G; Tanaka Michael; Hecht J Randolph; Heinrich Michael C; Fletcher Christopher D M; Crowley John J; Borden Ernest C
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(4):626-32.
2008: Bae S I; Cheriyath V; Jacobs B S; Reu F J; Borden E C
Reversal of methylation silencing of Apo2L/TRAIL receptor 1 (DR4) expression overcomes resistance of SK-MEL-3 and SK-MEL-28 melanoma cells to interferons (IFNs) or Apo2L/TRAIL.
Oncogene 2008;27(4):490-8.
2007: Borden Ernest C
Melanoma 2007: current state and preview of the future.
Seminars in oncology 2007;34(6):449-51.
2007: Borden Ernest C; Sen Ganes C; Uze Gilles; Silverman Robert H; Ransohoff Richard M; Foster Graham R; Stark George R
Interferons at age 50: past, current and future impact on biomedicine.
Nature reviews. Drug discovery 2007;6(12):975-90.
2007: Cheriyath Venugopalan; Glaser Keith B; Waring Jeffrey F; Baz Rachid; Hussein Mohamad A; Borden Ernest C
G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells.
The Journal of clinical investigation 2007;117(10):3107-17.
2007: Borden Ernest C
Augmentation of effects of interferon-stimulated genes by reversal of epigenetic silencing: potential application to melanoma.
Cytokine & growth factor reviews 2007;18(5-6):491-501.
2007: Li Jing; Lindner Daniel J; Farver Carol; Borden Ernest C; Yi Taolin
Efficacy of SSG and SSG/IFNalpha2 against human prostate cancer xenograft tumors in mice: a role for direct growth inhibition in SSG anti-tumor action.
Cancer chemotherapy and pharmacology 2007;60(3):341-9.
2007: Garland Linda L; Rankin Cathryn; Gandara David R; Rivkin Saul E; Scott Katherine M; Nagle Raymond B; Klein-Szanto Andres J P; Testa Joseph R; Altomare Deborah A; Borden Ernest C
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2406-13.
2007: Kalmadi S; Davis M; Dowlati A; O'Keefe S; Cline-Burkhardt M; Pelley R J; Borden E; Dreicer R; Bukowski R; Mekhail T
Phase I trial of three-weekly docetaxel, carboplatin and oral lenalidomide (Revlimid) in patients with advanced solid tumors.
Investigational new drugs 2007;25(3):211-6.
2007: Masci P; Olencki T; Wood L; Rybicki L; Jacobs B; Williams B; Faber P; Bukowski R; Tong K; Borden E C
Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family.
Clinical pharmacology and therapeutics 2007;81(3):354-61.
2007: Borden Ernest C
Adult sarcomas: a missed opportunity for sustained cooperative group translational and clinical research.
Oncology (Williston Park, N.Y.) 2007;21(2):247-9.
2007: Hsing Jeff M; Thakkar Snehal G; Borden Ernest C; Budd George T
Intimal pulmonary artery sarcoma presenting as dyspnea: case report.
International seminars in surgical oncology : ISSO 2007;4():14.
2006: Thakkar Snehal G; Peereboom David; Olencki Thomas; Jacobs Barbara; Elson Paul; Rybicki Lisa; Lindner Daniel J; Borden Ernest C
Short communication: phase I clinical and gene modulatory evaluation of tamoxifen and IFN-alpha2b.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006;26(11):800-3.
2006: Budd G Thomas; Cristofanilli Massimo; Ellis Mathew J; Stopeck Allison; Borden Ernest; Miller M Craig; Matera Jeri; Repollet Madeline; Doyle Gerald V; Terstappen Leon W M M; Hayes Daniel F
Circulating tumor cells versus imaging--predicting overall survival in metastatic breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6403-9.
2006: Reu Frederic J; Bae Soo In; Cherkassky Leonid; Leaman Douglas W; Lindner Daniel; Beaulieu Normand; MacLeod A Robert; Borden Ernest C
Overcoming resistance to interferon-induced apoptosis of renal carcinoma and melanoma cells by DNA demethylation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(23):3771-9.
2006: Taylor Kevin L; Oates Rhonda K; Grane Ron; Leaman Douglas W; Borden Ernest C; Lindner Daniel J
IFN-alpha1,8 inhibits tumor-induced angiogenesis in murine angiosarcomas.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2006;26(5):353-61.
2006: Andersen J B; Aaboe M; Borden E C; Goloubeva O G; Hassel B A; Orntoft T F
Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer.
British journal of cancer 2006;94(10):1465-71.
2006: Chow Warren A; Bedell Victoria; Gaytan Popsie; Borden Ernest; Goldblum John; Hicks David; Slovak Marilyn L
Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas.
Cancer genetics and cytogenetics 2006;166(2):95-100.
2006: Reu Frederic J; Leaman Douglas W; Maitra Ratan R; Bae Soo In; Cherkassky Leonid; Fox Mark W; Rempinski Donald R; Beaulieu Normand; MacLeod A Robert; Borden Ernest C
Expression of RASSF1A, an epigenetically silenced tumor suppressor, overcomes resistance to apoptosis induction by interferons.
Cancer research 2006;66(5):2785-93.
2006: Von Burton Gary; Rankin Cathy; Zalupski Mark M; Mills Glen M; Borden Ernest C; Karen Antman
Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma.
American journal of clinical oncology 2006;29(1):59-61.
2005: Fan Keke; Zhou Ming; Pathak Manas K; Lindner Daniel J; Altuntas Cengiz Z; Tuohy Vincent K; Borden Ernest C; Yi Taolin
Sodium stibogluconate interacts with IL-2 in anti-Renca tumor action via a T cell-dependent mechanism in connection with induction of tumor-infiltrating macrophages.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(10):7003-8.
2005: Giannakopoulos Nadia V; Luo Jiann-Kae; Papov Vladimir; Zou Weiguo; Lenschow Deborah J; Jacobs Barbara S; Borden Ernest C; Li Jun; Virgin Herbert W; Zhang Dong-Er
Proteomic identification of proteins conjugated to ISG15 in mouse and human cells.
Biochemical and biophysical research communications 2005;336(2):496-506.
2005: Borden Ernest C
Review: Milstein Award lecture: interferons and cancer: where from here?
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2005;25(9):511-27.
2005: Weng David E; Masci Paul A; Radka Susan F; Jackson T Elise; Weiss Patricia A; Ganapathi Ram; Elson Paul J; Capra William B; Parker Vann P; Lockridge Jennifer A; Cowens J Wayne; Usman Nassim; Borden Ernest C
A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors.
Molecular cancer therapeutics 2005;4(6):948-55.
2005: Rohatiner A Z S; Gregory W M; Peterson B; Borden E; Solal-Celigny P; Hagenbeek A; Fisher R I; Unterhalt M; Arranz R; Chisesi T; Aviles A; Lister T A
Meta-analysis to evaluate the role of interferon in follicular lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(10):2215-23.
2005: Singh Arun D; Borden Ernest C
Metastatic uveal melanoma.
Ophthalmology clinics of North America 2005;18(1):143-50, ix.
2004: Kelley Todd W; Borden Ernest C; Goldblum John R
Estrogen and progesterone receptor expression in uterine and extrauterine leiomyosarcomas: an immunohistochemical study.
Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry 2004;12(4):338-41.
2004: Budagian Vadim; Bulanova Elena; Orinska Zane; Pohl Thomas; Borden Ernest C; Silverman Robert; Bulfone-Paus Silvia
Reverse signaling through membrane-bound interleukin-15.
The Journal of biological chemistry 2004;279(40):42192-201.
2004: Budagian Vadim; Bulanova Elena; Orinska Zane; Ludwig Andreas; Rose-John Stefan; Saftig Paul; Borden Ernest C; Bulfone-Paus Silvia
Natural soluble interleukin-15Ralpha is generated by cleavage that involves the tumor necrosis factor-alpha-converting enzyme (TACE/ADAM17).
The Journal of biological chemistry 2004;279(39):40368-75.
2004: Chawla-Sarkar M; Bae S I; Reu F J; Jacobs B S; Lindner D J; Borden E C
Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis.
Cell death and differentiation 2004;11(8):915-23.
2004: Cui Xue-Fan; Imaizumi Tadaatsu; Yoshida Hidemi; Borden Ernest C; Satoh Kei
Retinoic acid-inducible gene-I is induced by interferon-gamma and regulates the expression of interferon-gamma stimulated gene 15 in MCF-7 cells.
Biochemistry and cell biology = Biochimie et biologie cellulaire 2004;82(3):401-5.
2004: Markman Maurie; Belinson Jerome; Webster Kenneth; Zanotti Kristine; Morrison Bei; Jacobs Barbara; Borden Ernest; Lindner Daniel
Phase 2 trial of interferon-beta as second-line treatment of ovarian cancer, fallopian tube cancer, or primary carcinoma of the peritoneum.
Oncology 2004;66(5):343-6.
2003: Leaman Douglas W; Chawla-Sarkar Mamta; Jacobs Barbara; Vyas Keyur; Sun Yaping; Ozdemir Aylin; Yi Taolin; Williams Bryan R; Borden Ernest C
Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2003;23(12):745-56.
2003: Glover Donna; Ibrahim Joseph; Kirkwood John; Glick John; Karp Daniel; Stewart James; Ewell Marian; Borden Ernest;
Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: an Eastern Cooperative Oncology Group Study (E1686).
Melanoma research 2003;13(6):619-26.
2003: Chawla-Sarkar Mamta; Bauer Joseph A; Lupica Joseph A; Morrison Bei H; Tang Zhuo; Oates Rhonda K; Almasan Alex; DiDonato Joseph A; Borden Ernest C; Lindner Daniel J
Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL.
The Journal of biological chemistry 2003;278(41):39461-9.
2003: Borden Ernest C; Baker Laurence H; Bell Robert S; Bramwell Vivien; Demetri George D; Eisenberg Burton L; Fletcher Christopher D M; Fletcher Jonathan A; Ladanyi Marc; Meltzer Paul; O'Sullivan Brian; Parkinson David R; Pisters Peter W T; Saxman Scott; Singer Samuel; Sundaram Murali; van Oosterom Allan T; Verweij Jaap; Waalen Jill; Weiss Sharon W; Brennan Murray F
Soft tissue sarcomas of adults: state of the translational science.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):1941-56.
2003: Chawla-Sarkar M; Lindner D J; Liu Y-F; Williams B R; Sen G C; Silverman R H; Borden E C
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis.
Apoptosis : an international journal on programmed cell death 2003;8(3):237-49.
2003: Vyas Keyur; Brassard Diana L; DeLorenzo Marc M; Sun Yaping; Grace Michael J; Borden Ernest C; Leaman Douglas W
Biologic activity of polyethylene glycol12000-interferon-alpha2b compared with interferon-alpha2b: gene modulatory and antigrowth effects in tumor cells.
Journal of immunotherapy (Hagerstown, Md. : 1997) 2003;26(3):202-11.
2003: Malakhov Michael P; Kim Keun Il; Malakhova Oxana A; Jacobs Barbara S; Borden Ernest C; Zhang Dong-Er
High-throughput immunoblotting. Ubiquitiin-like protein ISG15 modifies key regulators of signal transduction.
The Journal of biological chemistry 2003;278(19):16608-13.
2003: Hutson Thomas E; Molto Luis; Mekhail Tarek; Elson Paul; Finke James; Tannenbaum Charles; Borden Ernest; Dreicer Robert; Olencki Thomas; Bukowski Ronald M
Phase I trial of consensus interferon in patients with metastatic renal cell carcinoma: toxicity and immunological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(4):1354-60.
2003: Masci Paul; Bukowski Ronald M; Patten Phillip A; Osborn Blaire L; Borden Ernest C
New and modified interferon alfas: preclinical and clinical data.
Current oncology reports 2003;5(2):108-13.
2003: Bauer Joseph A; Morrison Bei H; Grane Ronald W; Jacobs Barbara S; Borden Ernest C; Lindner Daniel J
IFN-alpha2b and thalidomide synergistically inhibit tumor-induced angiogenesis.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2003;23(1):3-10.
2002: Pathak Manas K; Dhawan Deepika; Lindner Daniel J; Borden Ernest C; Farver Carol; Yi Taolin
Pentamidine is an inhibitor of PRL phosphatases with anticancer activity.
Molecular cancer therapeutics 2002;1(14):1255-64.
2002: Yi Taolin; Pathak Manas K; Lindner Daniel J; Ketterer Michael E; Farver Carol; Borden Ernest C
Anticancer activity of sodium stibogluconate in synergy with IFNs.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(10):5978-85.
2002: Borden Ernest C; Goldblum John R
Molecular characterization of soft tissue tumors.
Current oncology reports 2002;4(6):497-8.
2002: Leaman Douglas W; Chawla-Sarkar Mamta; Vyas Keyur; Reheman Monila; Tamai Katsuyuki; Toji Singo; Borden Ernest C
Identification of X-linked inhibitor of apoptosis-associated factor-1 as an interferon-stimulated gene that augments TRAIL Apo2L-induced apoptosis.
The Journal of biological chemistry 2002;277(32):28504-11.
2002: Masci Paul; Borden Ernest C
Malignant melanoma: treatments emerging, but early detection is still key.
Cleveland Clinic journal of medicine 2002;69(7):529, 533-4, 536-8 passim.
2002: Chawla-Sarkar Mamta; Leaman Douglas W; Jacobs Barbara S; Borden Ernest C
IFN-beta pretreatment sensitizes human melanoma cells to TRAIL/Apo2 ligand-induced apoptosis.
Journal of immunology (Baltimore, Md. : 1950) 2002;169(2):847-55.
2002: Padovan Elisabetta; Terracciano Luigi; Certa Ulrich; Jacobs Barbara; Reschner Anca; Bolli Martin; Spagnoli Giulio C; Borden Ernest C; Heberer Michael
Interferon stimulated gene 15 constitutively produced by melanoma cells induces e-cadherin expression on human dendritic cells.
Cancer research 2002;62(12):3453-8.
2002: Chawla-Sarkar Mamta; Leaman Douglas W; Jacobs Barbara S; Tuthill Ralph J; Chatterjee-Kishore Moitreyee; Stark George R; Borden Ernest C
Resistance to interferons in melanoma cells does not correlate with the expression or activation of signal transducer and activator of transcription 1 (Stat1).
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2002;22(5):603-13.
2001: Smalley R V; Weller E; Hawkins M J; Oken M M; O'Connell M J; Haase-Statz S; Borden E C
Final analysis of the ECOG I-COPA trial (E6484) in patients with non-Hodgkin's lymphoma treated with interferon alfa (IFN-alpha2a) plus an anthracycline-based induction regimen.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2001;15(7):1118-22.
2001: Chawla-Sarkar M; Leaman D W; Borden E C
Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1821-31.
2000: Sandberg J A; Parker V P; Blanchard K S; Sweedler D; Powell J A; Kachensky A; Bellon L; Usman N; Rossing T; Borden E; Blatt L M
Pharmacokinetics and tolerability of an antiangiogenic ribozyme (ANGIOZYME) in healthy volunteers.
Journal of clinical pharmacology 2000;40(12 Pt 2):1462-9.
2000: Borden E C
Melanoma and pregnancy.
Seminars in oncology 2000;27(6):654-6.
2000: Borden E C
Reducing primary melanoma mortality.
Current oncology reports 2000;2(4):289-91.
2000: Borden E C; Lindner D; Dreicer R; Hussein M; Peereboom D
Second-generation interferons for cancer: clinical targets.
Seminars in cancer biology 2000;10(2):125-44.
1999: Borden E C; Esserman L; Linder D J; Campbell M J; Fulton A M
Biological therapies for breast carcinoma: concepts for improvement in survival.
Seminars in oncology 1999;26(4 Suppl 12):28-40.
1998: Rosenthal M A; Green M; Wiernik P; Borden E C; Marsh J C; Haller D G
Epirubicin has modest single-agent activity in head and neck cancer but limited activity in metastatic melanoma and colorectal cancer: phase II studies by the Eastern Cooperative Oncology Group.
American journal of clinical oncology 1998;21(5):509-12.
1998: Walter M R; Bordens R; Nagabhushan T L; Williams B R; Herberman R B; Dinarello C A; Borden E C; Trotta P P; Pestka S; Pfeffer L M
Review of recent developments in the molecular characterization of recombinant alfa interferons on the 40th anniversary of the discovery of interferon.
Cancer biotherapy & radiopharmaceuticals 1998;13(3):143-54.
1998: Pfeffer L M; Dinarello C A; Herberman R B; Williams B R; Borden E C; Bordens R; Walter M R; Nagabhushan T L; Trotta P P; Pestka S
Biological properties of recombinant alpha-interferons: 40th anniversary of the discovery of interferons.
Cancer research 1998;58(12):2489-99.
1998: Borden E C; Parkinson D
A perspective on the clinical effectiveness and tolerance of interferon-alpha.
Seminars in oncology 1998;25(1 Suppl 1):3-8.
1998: Borden E C
Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon beta 1a (IFN beta-1a) products administered intramuscularly in healthy male and female volunteers.
Pharmaceutical research 1998;15(1):2-3.
1998: Hochster H; Oratz R; Ettinger D S; Borden E
A phase II study of Didemnin B (NSC 325319) in advanced malignant melanoma: an Eastern Cooperative Oncology Group study (PB687).
Investigational new drugs 1998;16(3):259-63.
1997: Lindner D J; Borden E C
Synergistic antitumor effects of a combination of interferon and tamoxifen on estrogen receptor-positive and receptor-negative human tumor cell lines in vivo and in vitro.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1997;17(11):681-93.
1997: Mackowiak P A; Bartlett J G; Borden E C; Goldblum S E; Hasday J D; Munford R S; Nasraway S A; Stolley P D; Woodward T E
Concepts of fever: recent advances and lingering dogma.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1997;25(1):119-38.
1997: Lindner D J; Borden E C; Kalvakolanu D V
Synergistic antitumor effects of a combination of interferons and retinoic acid on human tumor cells in vitro and in vivo.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(6):931-7.
1997: Lindner D J; Kalvakolanu D V; Borden E C
Increasing effectiveness of interferon-alpha for malignancies.
Seminars in oncology 1997;24(3 Suppl 9):S9-99-S9-104.
1997: Lindner D J; Borden E C
Effects of tamoxifen and interferon-beta or the combination on tumor-induced angiogenesis.
International journal of cancer. Journal international du cancer 1997;71(3):456-61.
1997: Abdul-Ahad A K; Galazka A R; Revel M; Biffoni M; Borden E C
Incidence of antibodies to interferon-beta in patients treated with recombinant human interferon-beta 1a from mammalian cells.
Cytokines, cellular & molecular therapy 1997;3(1):27-32.
1997: Kirkwood J M; Bryant J; Schiller J H; Oken M M; Borden E C; Whiteside T L
Immunomodulatory function of interferon-gamma in patients with metastatic melanoma: results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. Eastern Cooperative Oncology Group.
Journal of immunotherapy (Hagerstown, Md. : 1997) 1997;20(2):146-57.
1997: Lindner D J; Kolla V; Kalvakolanu D V; Borden E C
Tamoxifen enhances interferon-regulated gene expression in breast cancer cells.
Molecular and cellular biochemistry 1997;167(1-2):169-77.
1996: Taylor J L; D'Cunha J; Tom P; O'Brien W J; Borden E C
Production of ISG-15, an interferon-inducible protein, in human corneal cells.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(11):937-40.
1996: Byhardt R W; Vaickus L; Witt P L; Chang A Y; McAuliffe T; Wilson J F; Lawton C A; Breitmeyer J; Alger M E; Borden E C
Recombinant human interferon-beta (rHuIFN-beta) and radiation therapy for inoperable non-small cell lung cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(11):891-902.
1996: D'Cunha J; Ramanujam S; Wagner R J; Witt P L; Knight E; Borden E C
In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine.
Journal of immunology (Baltimore, Md. : 1950) 1996;157(9):4100-8.
1996: Borden E C; Wadler S
Interferons as biochemical modulators.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(10):2627-30.
1996: Borden E C; Parkinson D
Interferons: effectiveness, toxicities, and costs.
Annals of internal medicine 1996;125(7):614-6.
1996: Witt P L; Zahir S; Ritch P S; McAuliffe T M; Ewel C H; Borden E C
Phase I/IB study of polyadenylic-polyuridylic acid in patients with advanced malignancies: clinical and biologic effects.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(8):631-5.
1996: Keever-Taylor C A; Witt P L; Truitt R L; Ramanujam S; Borden E C; Ritch P S
Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1996;19(3):231-43.
1996: Kolla V; Lindner D J; Xiao W; Borden E C; Kalvakolanu D V
Modulation of interferon (IFN)-inducible gene expression by retinoic acid. Up-regulation of STAT1 protein in IFN-unresponsive cells.
The Journal of biological chemistry 1996;271(18):10508-14.
1996: Schiller J H; Pugh M; Kirkwood J M; Karp D; Larson M; Borden E
Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(1):29-36.
1996: Kirkwood J M; Strawderman M H; Ernstoff M S; Smith T J; Borden E C; Blum R H
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(1):7-17.
1996: D'Cunha J; Knight E; Haas A L; Truitt R L; Borden E C
Immunoregulatory properties of ISG15, an interferon-induced cytokine.
Proceedings of the National Academy of Sciences of the United States of America 1996;93(1):211-5.
1996: Albert D M; Ryan L M; Borden E C
Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis.
Archives of ophthalmology 1996;114(1):107-8.
1996: Kalvakolanu D V; Borden E C
An overview of the interferon system: signal transduction and mechanisms of action.
Cancer investigation 1996;14(1):25-53.
1995: Sivinski C L; Lindner D J; Borden E C; Tempero M A
Modulation of tumor-associated antigen expression on human pancreatic and prostate carcinoma cells in vitro by alpha- and gamma-interferons.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1995;18(3):156-65.
1995: Falkson G; Lipsitz S; Borden E; Simson I; Haller D
Hepatocellular carcinoma. An ECOG randomized phase II study of beta-interferon and menogaril.
American journal of clinical oncology 1995;18(4):287-92.
1995: Borden E C; Waalen J; Schreiber R; Williams B
Response and resistance to interferons and interacting cytokines.
Journal of the National Cancer Institute 1995;87(4):257-64.
1994: Borden E C
Innovative treatment strategies for non-Hodgkin's lymphoma and multiple myeloma.
Seminars in oncology 1994;21(6 Suppl 14):14-22.
1994: Kalvakolanu D V; Mannino S B; Thornton A; Ozato K; Borden E C
Transcriptional induction of genes by IFN-beta in mouse cells is regulated by a transcription factor similar to human ISGF-3.
Antiviral research 1994;25(2):91-103.
1994: Moore D M; Kalvakolanu D V; Lippman S M; Kavanagh J J; Hong W K; Borden E C; Paredes-Espinoza M; Krakoff I H
Retinoic acid and interferon in human cancer: mechanistic and clinical studies.
Seminars in hematology 1994;31(4 Suppl 5):31-7.
1994: Borden E C; Chin P
Interleukin-6: a cytokine with potential diagnostic and therapeutic roles.
The Journal of laboratory and clinical medicine 1994;123(6):824-9.
1993: Borden E C; Waalen J; Liberati A M; Grignani F
Molecular diagnosis and monitoring of leukemia and lymphoma.
Leukemia research 1993;17(12):1073-8.
1993: Witt P L; Ritch P S; Reding D; McAuliffe T L; Westrick L; Grossberg S E; Borden E C
Phase I trial of an oral immunomodulator and interferon inducer in cancer patients.
Cancer research 1993;53(21):5176-80.
1993: Nolten W E; Goldstein D; Lindstrom M; McKenna M V; Carlson I H; Trump D L; Schiller J; Borden E C; Ehrlich E N
Effects of cytokines on the pituitary-adrenal axis in cancer patients.
Journal of interferon research 1993;13(5):349-57.
1993: Borden E C; Lotan R; Levens D; Young C W; Waxman S
Differentiation therapy of cancer: laboratory and clinical investigations.
Cancer research 1993;53(17):4109-15.
1993: Borden E C; Schlom J
Williamsburg Conference on Biological and Immunological Treatments for Cancer, 1992.
Journal of the National Cancer Institute 1993;85(16):1288-93.
1993: Brar D W; Borden E C; Proctor R A
Recombinant interferon-gamma preserves human granulocyte bactericidal and chemoluminescence activities.
The Journal of infectious diseases 1993;168(1):128-34.
1993: Ryan L; Kramar A; Borden E
Prognostic factors in metastatic melanoma.
Cancer 1993;71(10):2995-3005.
1993: Witt P L; Storer B E; Bryan G T; Brown R R; Flashner M; Larocca A T; Colby C B; Borden E C
Pharmacodynamics of biological response in vivo after single and multiple doses of interferon-beta.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(3):191-200.
1993: Witt P L; Marié I; Robert N; Irizarry A; Borden E C; Hovanessian A G
Isoforms p69 and p100 of 2',5'-oligoadenylate synthetase induced differentially by interferons in vivo and in vitro.
Journal of interferon research 1993;13(1):17-23.
1993: Gambacorti-Passerini C; Hank J A; Albertini M R; Borchert A A; Moore K H; Schiller J H; Bechhofer R; Borden E C; Storer B; Sondel P M
A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;13(1):43-8.
1993: Gibson D F; Johnson D A; Goldstein D; Langan-Fahey S M; Borden E C; Jordan V C
Human recombinant interferon-beta SER and tamoxifen: growth suppressive effects for the human breast carcinoma MCF-7 grown in the athymic mouse.
Breast cancer research and treatment 1993;25(2):141-50.
1992: Borden E C; Kim K; Ryan L; Blum R H; Shiraki M; Tormey D C; Comis R L; Hahn R G; Parkinson D R
Phase II trials of interferons-alpha and -beta in advanced sarcomas.
Journal of interferon research 1992;12(6):455-8.
1992: Witt P L; Goldstein D; Storer B E; Grossberg S E; Flashner M; Colby C B; Borden E C
Absence of biological effects of orally administered interferon-beta ser.
Journal of interferon research 1992;12(6):411-3.
1992: Falkson G; Hunt M; Borden E C; Hayes J A; Falkson C I; Smith T J
An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.
Investigational new drugs 1992;10(4):337-43.
1992: Smalley R V; Andersen J W; Hawkins M J; Bhide V; O'Connell M J; Oken M M; Borden E C
Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma.
The New England journal of medicine 1992;327(19):1336-41.
1992: Hansen R M; Borden E C
Current status of interferons in the treatment of cancer.
Oncology (Williston Park, N.Y.) 1992;6(11):19-24; discussion 26, 29.
1992: Schectman G; Kaul S; Mueller R A; Borden E C; Kissebah A H
The effect of interferon on the metabolism of LDLs.
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 1992;12(9):1053-62.
1992: Norioka K; Borden E C; Auerbach R
Inhibitory effects of cytokines on vascular endothelial cells: synergistic interactions among interferon-gamma, tumor necrosis factor-alpha, and interleukin-1.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1992;12(1):13-8.
1992: Sidky Y A; Borden E C; Weeks C E; Reiter M J; Hatcher J F; Bryan G T
Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine.
Cancer research 1992;52(13):3528-33.
1992: Meyer K C; Cornwell R; Carlin J M; Powers C; Irizarry A; Byrne G I; Borden E C
Effects of interferons beta or gamma on neopterin biosynthesis and tryptophan degradation by human alveolar macrophages in vitro: synergy with lipopolysaccharide.
American journal of respiratory cell and molecular biology 1992;6(6):639-46.
1992: Merritt J A; Ball L A; Sielaff K M; Meltzer D M; Borden E C
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.
Journal of interferon research 1992;Spec No():7-16.
1992: Greiner J W; Guadagni F; Goldstein D; Smalley R V; Borden E C; Simpson J F; Molinolo A; Schlom J
Intraperitoneal administration of interferon-gamma to carcinoma patients enhances expression of tumor-associated glycoprotein-72 and carcinoembryonic antigen on malignant ascites cells.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):735-46.
1992: Borden E C
Interferons--expanding therapeutic roles.
The New England journal of medicine 1992;326(22):1491-3.
1992: Borden E C
Interferons: pleiotropic cellular modulators.
Clinical immunology and immunopathology 1992;62(1 Pt 2):S18-24.
1992: Borden E
Cytokines and monoclonal antibodies: an introduction of their current and future applications to cancer and other diseases.
Medical Section proceedings : the ... annual Meeting of the Medical Section of the American Council of Life Insurance. American Council of Life Insurance. Medical Section. Meeting 1992;():51-62.
1991: Goldstein D; O'Leary M; Mitchen J; Borden E C; Wilding G
Effects of interferon beta ser and transforming growth factor beta on prostatic cell lines.
The Journal of urology 1991;146(4):1173-7.
1991: Schiller J H; Lindstrom M; Witt P L; Hank J A; Mahvi D; Wagner R J; Sondel P; Borden E C
Immunological effects of levamisole in vitro.
Journal of immunotherapy : official journal of the Society for Biological Therapy 1991;10(5):297-306.
1991: Recht M; Borden E C; Knight E
A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma.
Journal of immunology (Baltimore, Md. : 1950) 1991;147(8):2617-23.
1991: Meyer K C; Powers C; Cornwell R; Borden E C
Priming of human alveolar macrophages and blood monocytes for superoxide anion release by interferons and lipopolysaccharide.
Journal of interferon research 1991;11(5):283-90.
1991: Greiner J W; Guadagni F; Goldstein D; Borden E C; Ritts R E; Witt P; LoBuglio A F; Saleh M N; Schlom J
Evidence for the elevation of serum carcinoembryonic antigen and tumor-associated glycoprotein-72 levels in patients administered interferons.
Cancer research 1991;51(16):4155-63.
1991: Witt P L; Spear G T; Lindstrom M J; Kessler H A; Borden E C; Phair J; Landay A L
2',5'-oligoadenylate synthetase, neopterin and beta 2-microglobulin in asymptomatic HIV-infected individuals.
AIDS (London, England) 1991;5(3):289-93.
1991: Borden E C
Biotechnology: its impact on medicine and oncology.
Annals of the Academy of Medicine, Singapore 1991;20(2):255-9.
1991: Greiner J W; Smalley R V; Borden E C; Martin E W; Guadagni F; Roselli M; Schlom J
Applications of monoclonal antibodies and recombinant cytokines for the treatment of human colorectal and other carcinomas.
Journal of surgical oncology. Supplement 1991;2():9-13.
1991: Ozaki Y; Borden E C; Smalley R V; Brown R R
Interferon type I and II antagonism: a novel regulatory mechanism of indoleamine dioxygenase induction in human peripheral blood monocytes and peritoneal macrophages.
Advances in experimental medicine and biology 1991;294():547-53.
1991: Brown R R; Ozaki Y; Datta S P; Borden E C; Sondel P M; Malone D G
Implications of interferon-induced tryptophan catabolism in cancer, auto-immune diseases and AIDS.
Advances in experimental medicine and biology 1991;294():425-35.
1990: Borden E C; Rinehart J J; Storer B E; Trump D L; Paulnock D M; Teitelbaum A P
Biological and clinical effects of interferon-beta ser at two doses.
Journal of interferon research 1990;10(6):559-70.
1990: Goldstein D; Cheuvart B; Trump D L; Shiraki M; Comis R L; Tormey D C; Harris J E; Borden E C
Phase II trial of carboplatin in soft-tissue sarcoma.
American journal of clinical oncology 1990;13(5):420-3.
1990: Schiller J H; Storer B; Paulnock D M; Brown R R; Datta S P; Witt P L; Borden E C
A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans.
The Journal of clinical investigation 1990;86(4):1211-21.
1990: Borden E C; Amato D A; Edmonson J H; Ritch P S; Shiraki M
Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas.
Cancer 1990;66(5):862-7.
1990: Schiller J H; Horisberger M A; Bittner G; Carlin J M; Storer B; Byrne G I; Willson J K; Borden E C
Effects of combinations of interferon-beta ser and interferon-gamma on interferon-inducible proteins and on the cell cycle.
Journal of biological response modifiers 1990;9(4):368-77.
1990: Bergsagel D E; von Wussow P; Alexanian R; Avvisati G; Bataille R; Barlogie B; Borden E; Caligaris-Cappio F; Deicher H; Durie B G
Interferons in the treatment of multiple myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1990;8(8):1444-5.
1990: Witt P L; Spear G T; Helgeson D O; Lindstrom M J; Smalley R V; Borden E C
Basal and interferon-induced 2',5'-oligoadenylate synthetase in human monocytes, lymphocytes, and peritoneal macrophages.
Journal of interferon research 1990;10(4):393-402.
1990: Schiller J H; Storer B; Witt P L; Nelson B; Brown R R; Horisberger M; Grossberg S; Borden E C
Biological and clinical effects of the combination of beta- and gamma-interferons administered as a 5-day continuous infusion.
Cancer research 1990;50(15):4588-94.
1990: Borden E C; Creekmore S P
Cancer therapy with combinations of biological response modifiers and cytotoxics: an update.
Cancer cells (Cold Spring Harbor, N.Y. : 1989) 1990;2(7):217-20.
1990: Rosenblum M G; Yung W K; Kelleher P J; Ruzicka F; Steck P A; Borden E C
Growth inhibitory effects of interferon-beta but not interferon-alpha on human glioma cells: correlation of receptor binding, 2',5'-oligoadenylate synthetase and protein kinase activity.
Journal of interferon research 1990;10(2):141-51.
1990: Sedgwick J B; Frick W E; Sondel P M; Hank J A; Borden E; Busse W W
The appearance of hypodense eosinophils during interleukin-2 treatment.
The Journal of allergy and clinical immunology 1990;85(3):557-66.
1990: Borden E C; Sondel P M
Lymphokines and cytokines as cancer treatment. Immunotherapy realized.
Cancer 1990;65(3 Suppl):800-14.
1990: Trump D L; Ravdin P M; Borden E C; Magers C F; Whisnant J K
Interferon-alpha-n1 and continuous infusion vinblastine for treatment of advanced renal cell carcinoma.
Journal of biological response modifiers 1990;9(1):108-11.
1990: Borden E C; Sidky Y A; Ertürk E; Wierenga W; Bryan G T
Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Cancer research 1990;50(4):1071-4.
1990: Earhart R H; Amato D J; Chang A Y; Borden E C; Shiraki M; Dowd M E; Comis R L; Davis T E; Smith T J
Phase II trial of 6-diazo-5-oxo-L-norleucine versus aclacinomycin-A in advanced sarcomas and mesotheliomas.
Investigational new drugs 1990;8(1):113-9.
1990: Robinson S P; Goldstein D; Witt P L; Borden E C; Jordan V C
Inhibition of hormone-dependent and independent breast cancer cell growth in vivo and in vitro with the antiestrogen toremifene and recombinant human interferon-alpha 2.
Breast cancer research and treatment 1990;15(2):95-101.
1990: Litton G J; Hong R; Grossberg S E; Vechlekar D; Goodavish C N; Borden E C
Biological and clinical effects of the oral immunomodulator 3,6-bis(2-piperidinoethoxy)acridine trihydrochloride in patients with malignancy.
Journal of biological response modifiers 1990;9(1):61-70.
1990: Schiller J H; Bushmeyer S M; Ruzicka F J; Princler G L; Faltynek C R; Borden E C
Modulation of interferon receptor expression during combination beta ser-interferon and gamma-interferon treatment of human colon carcinoma cells.
Cancer research 1990;50(1):26-31.
1990: Rosenzweig I B; Wiebe D A; Hank J A; Albers J J; Adolphson J L; Borden E; Shrago E S; Sondel P M
Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein, and C-reactive protein.
Biotherapy (Dordrecht, Netherlands) 1990;2(3):193-8.
1989: Schmitz J L; Carlin J M; Borden E C; Byrne G I
Beta interferon inhibits Toxoplasma gondii growth in human monocyte-derived macrophages.
Infection and immunity 1989;57(10):3254-6.
1989: Larocca A P; Leung S C; Marcus S G; Colby C B; Borden E C
Evaluation of neutralizing antibodies in patients treated with recombinant interferon-beta ser.
Journal of interferon research 1989;9 Suppl 1():S51-60.
1989: Gottardis M M; Wagner R J; Borden E C; Jordan V C
Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in vivo and in vitro.
Cancer research 1989;49(17):4765-9.
1989: Paulnock D M; Havlin K A; Storer B M; Spear G T; Sielaff K M; Borden E C
Induced proteins in human peripheral mononuclear cells over a range of clinically tolerable doses of interferon-gamma.
Journal of interferon research 1989;9(4):457-73.
1989: Shiraki M; Enterline H T; Brooks J J; Cooper N S; Hirschl S; Roth J A; Rao U N; Enzinger F M; Amato D A; Borden E C
Pathologic analysis of advanced adult soft tissue sarcomas, bone sarcomas, and mesotheliomas. The Eastern Cooperative Oncology Group (ECOG) experience.
Cancer 1989;64(2):484-90.
1989: Goldstein D; Sielaff K M; Storer B E; Brown R R; Datta S P; Witt P L; Teitelbaum A P; Smalley R V; Borden E C
Human biologic response modification by interferon in the absence of measurable serum concentrations: a comparative trial of subcutaneous and intravenous interferon-beta serine.
Journal of the National Cancer Institute 1989;81(14):1061-8.
1989: Schiller J H; Hawkins M J; O'Connell M J; Sielaff K; Borden E C
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Journal of biological response modifiers 1989;8(3):252-61.
1989: Carlin J M; Borden E C; Byrne G I
Interferon-induced indoleamine 2,3-dioxygenase activity inhibits Chlamydia psittaci replication in human macrophages.
Journal of interferon research 1989;9(3):329-37.
1989: Carlin J M; Ozaki Y; Byrne G I; Brown R R; Borden E C
Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects.
Experientia 1989;45(6):535-41.
1989: Goldstein D; Bushmeyer S M; Witt P L; Jordan V C; Borden E C
Effects of type I and II interferons on cultured human breast cells: interaction with estrogen receptors and with tamoxifen.
Cancer research 1989;49(10):2698-702.
1989: Carlin J M; Borden E C; Byrne G I
Enhancement of indoleamine 2,3-dioxygenase activity in cancer patients receiving interferon-beta Ser.
Journal of interferon research 1989;9(2):167-73.
1989: Guadagni F; Schlom J; Johnston W W; Szpak C A; Goldstein D; Smalley R; Simpson J F; Borden E C; Pestka S; Greiner J W
Selective interferon-induced enhancement of tumor-associated antigens on a spectrum of freshly isolated human adenocarcinoma cells.
Journal of the National Cancer Institute 1989;81(7):502-12.
1989: Robins H I; Sielaff K M; Storer B; Hawkins M J; Borden E C
Phase I trial of human lymphoblastoid interferon with whole body hyperthermia in advanced cancer.
Cancer research 1989;49(6):1609-15.
1989: Carlin J M; Borden E C; Sondel P M; Byrne G I
Interferon-induced indoleamine 2,3-dioxygenase activity in human mononuclear phagocytes.
Journal of leukocyte biology 1989;45(1):29-34.
1989: Nelson B E; Borden E C
Interferons: biological and clinical effects.
Seminars in surgical oncology 1989;5(6):391-401.
1988: Schiller J H; Storer B; Bittner G; Willson J K; Borden E C
Phase II trial of a combination of interferon-beta ser and interferon-gamma in patients with advanced malignant melanoma.
Journal of interferon research 1988;8(5):581-9.
1988: Borden E C; Hawkins M J; Sielaff K M; Storer B M; Schiesel J D; Smalley R V
Clinical and biological effects of recombinant interferon-beta administered intravenously daily in phase I trial.
Journal of interferon research 1988;8(3):357-66.
1988: Cheng Y S; Becker-Manley M F; Rucker R G; Borden E C
Accumulation of guanylate binding proteins in patients treated with interferons.
Journal of interferon research 1988;8(3):385-91.
1988: Borden E C; Sidky Y A; Hatcher J F; Bryan G T
Schedule-dependent variations in the response of murine P388 leukemia to cyclophosphamide in combination with interferons-alpha/beta.
Cancer research 1988;48(9):2329-34.
1988: Havlin K A; Inglot A D; Willson J K; Borden E C; Grossberg S; Szulc B; Gladysz A; Groehlich B
Lack of interferon production by dipyridamole.
Journal of interferon research 1988;8(2):135-6.
1988: Spear G T; Paulnock D M; Helgeson D O; Borden E C
Requirement of differentiative signals of both interferon-gamma and 1,25-dihydroxyvitamin D3 for induction and secretion of interleukin-1 by HL-60 cells.
Cancer research 1988;48(7):1740-4.
1988: Borden E C
Augmented tumor-associated antigen expression by interferons.
Journal of the National Cancer Institute 1988;80(3):148-9.
1988: Borden E C; Bradley E C; Evans C H; Fox C F; Metzgar R S; Mitchell M S; Weinstein J N
Biotechnology products in cancer therapy: a colloquium.
Cancer research 1988;48(1):223-5.
1988: Borden E C
Effects of interferons in neoplastic diseases of man.
Pharmacology & therapeutics 1988;37(2):213-29.
1987: Ruzicka F J; Jach M E; Borden E C
Binding of recombinant-produced interferon beta ser to human lymphoblastoid cells. Evidence for two binding domains.
The Journal of biological chemistry 1987;262(33):16142-9.
1987: Schiller J H; Storer B; Willson J K; Borden E C
Phase I trial of combinations of recombinant interferons beta(ser) and gamma in patients with advanced malignancy.
Cancer treatment reports 1987;71(10):945-52.
1987: Rosenzweig I B; Wiebe D A; Borden E C; Storer B; Shrago E S
Plasma lipoprotein changes in humans induced by beta-interferon.
Atherosclerosis 1987;67(2-3):261-7.
1987: Borden E C; Rosenzweig I B; Byrne G I
Interferons: from virus inhibitor to modulator of amino acid and lipid metabolism.
Journal of interferon research 1987;7(5):591-6.
1987: Carlin J M; Borden E C; Sondel P M; Byrne G I
Biologic-response-modifier-induced indoleamine 2,3-dioxygenase activity in human peripheral blood mononuclear cell cultures.
Journal of immunology (Baltimore, Md. : 1950) 1987;139(7):2414-8.
1987: Sidky Y A; Borden E C
Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses.
Cancer research 1987;47(19):5155-61.
1987: Konrad M W; Childs A L; Merigan T C; Borden E C
Assessment of the antigenic response in humans to a recombinant mutant interferon beta.
Journal of clinical immunology 1987;7(5):365-75.
1987: Ruzicka F J; Schmid S M; Groveman D S; Cummings K B; Borden E C
Variation in the binding of 125I-labeled interferon-beta ser to cellular receptors during growth of human renal and bladder carcinoma cells in vitro.
Cancer research 1987;47(17):4582-9.
1987: Spear G T; Paulnock D M; Jordan R L; Meltzer D M; Merritt J A; Borden E C
Enhancement of monocyte class I and II histocompatibility antigen expression in man by in vivo beta-interferon.
Clinical and experimental immunology 1987;69(1):107-15.
1987: Borden E C; Amato D A; Rosenbaum C; Enterline H T; Shiraki M J; Creech R H; Lerner H J; Carbone P P
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(6):840-50.
1987: Falkson G; Vorobiof D A; Simson I W; Borden E C
Phase II trial of acivicin in malignant mesothelioma.
Cancer treatment reports 1987;71(5):545-6.
1987: Borden E C
Progress in management of malignant melanoma.
Wisconsin medical journal 1987;86(4):23-5.
1987: Trump D L; Elson P J; Borden E C; Harris J E; Tuttle R L; Whisnant J K; Oken M M; Carignan J R; Ruckdeschel J C; Davis T E
High-dose lymphoblastoid interferon in advanced renal cell carcinoma: an Eastern Cooperative Oncology Group Study.
Cancer treatment reports 1987;71(2):165-9.
1987: Samson M K; Wasser L P; Borden E C; Wanebo H J; Creech R H; Phillips M; Baker L H
Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1987;5(1):86-91.
1987: Amato D A; Bruckner H; Guerry D; Ash A; Falkson G; Borden E C; Creech R H; Savlov E D; Cunningham T J
Phase II evaluation of dibromodulcitol and actinomycin D, hydroxyurea, and cyclophosphamide in previously untreated patients with malignant melanoma.
Investigational new drugs 1987;5(3):293-7.
1987: Kuebler J P; Oberley T D; Meisner L F; Sidky Y A; Reznikoff C A; Borden E C; Cummings K B; Bryan G T
Effect of interferon alpha, interferon beta, and interferon gamma on the in vitro growth of human renal adenocarcinoma cells.
Investigational new drugs 1987;5(1):21-9.
1986: Massaro E R; Borden E C; Hawkins M J; Wiebe D A; Shrago E
Effects of recombinant interferon-alpha 2 treatment upon lipid concentrations and lipoprotein composition.
Journal of interferon research 1986;6(6):655-62.
1986: Schiller J H; Willson J K; Bittner G; Wolberg W H; Hawkins M J; Borden E C
Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay.
Journal of interferon research 1986;6(6):615-25.
1986: Edwards B S; Fuhlbrigge R C; Borden E C
Separation of human natural killer cell subpopulations differentially responsive to interferon potentiation.
Journal of interferon research 1986;6(4):361-72.
1986: Sidky Y A; Borden E C; Wierenga W; Bryan G T
Inhibitory effects of interferon-inducing pyrimidinones on the growth of transplantable mouse bladder tumors.
Cancer research 1986;46(8):3798-802.
1986: Byrne G I; Lehmann L K; Kirschbaum J G; Borden E C; Lee C M; Brown R R
Induction of tryptophan degradation in vitro and in vivo: a gamma-interferon-stimulated activity.
Journal of interferon research 1986;6(4):389-96.
1986: Merritt J A; Ball L A; Sielaff K M; Meltzer D M; Borden E C
Modulation of 2',5'-oligoadenylate synthetase in patients treated with alpha-interferon: effects of dose, schedule, and route of administration.
Journal of interferon research 1986;6(3):189-98.
1986: Borden E C; Hawkins M J
Biologic response modifiers as adjuncts to other therapeutic modalities.
Seminars in oncology 1986;13(2):144-52.
1986: Quesada J R; Alexanian R; Hawkins M; Barlogie B; Borden E; Itri L; Gutterman J U
Treatment of multiple myeloma with recombinant alpha-interferon.
Blood 1986;67(2):275-8.
1986: Schiller J H; Groveman D S; Schmid S M; Willson J K; Cummings K B; Borden E C
Synergistic antiproliferative effects of human recombinant alpha 54- or beta ser-interferon with gamma-interferon on human cell lines of various histogenesis.
Cancer research 1986;46(2):483-8.
1986: Chang A Y; Kuebler J P; Tormey D C; Anderson S; Pandya K J; Borden E C; Davis T E; Trump D L
Phase II evaluation of a combination of mitomycin C, vincristine, and cisplatin in advanced non-small cell lung cancer.
Cancer 1986;57(1):54-9.
1986: Arseneau J C; Schoenfeld D A; Borden E C
A phase II study of dihydroxyanthracenedione (DHAD, mitoxantrone, NSC 301739) in advanced malignant melanoma.
Investigational new drugs 1986;4(1):53-6.
1986: Smalley R V; Borden E C
Interferons: current status and future directions of this prototypic biological.
Springer seminars in immunopathology 1986;9(1):73-83.
1985: Borden E C; Verma A K; Wolberg W H
Potential role of polyribonucleotides in human neoplastic diseases.
Journal of biological response modifiers 1985;4(6):676-9.
1985: Hawkins M J; Levin M; Borden E C
An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.
Journal of biological response modifiers 1985;4(6):664-8.
1985: Edwards B S; Merritt J A; Fuhlbrigge R C; Borden E C
Low doses of interferon alpha result in more effective clinical natural killer cell activation.
The Journal of clinical investigation 1985;75(6):1908-13.
1985: Borden E C; Sidky Y A; Groveman D S; Bryan G T
Antitumor effects of polyribonucleotides for mouse transitional cell carcinoma enhanced by cyclophosphamide.
Cancer research 1985;45(1):45-50.
1985: Merritt J A; Borden E C; Ball L A
Measurement of 2',5'-oligoadenylate synthetase in patients receiving interferon-alpha.
Journal of interferon research 1985;5(1):191-8.
1985: Merritt J A; Meltzer D M; Ball L A; Borden E C
2-5A synthetase activity in patients with metastatic carcinoma and its response to interferon treatment.
Progress in clinical and biological research 1985;202():423-30.
1985: Amato D A; Borden E C; Shiraki M; Enterline H T; Rosenbaum C; Davis H L; Paul A R; Stevens C M; Lerner H J
Evaluation of bleomycin, chlorozotocin, MGBG, and bruceantin in patients with advanced soft tissue sarcoma, bone sarcoma, or mesothelioma.
Investigational new drugs 1985;3(4):397-401.
1984: Hawkins M J; Krown S E; Borden E C; Krim M; Real F X; Edwards B S; Anderson S A; Cunningham-Rundles S; Oettgen H F
American cancer society Phase I trial of naturally produced beta-interferon.
Cancer research 1984;44(12 Pt 1):5934-8.
1984: Groveman D S; Borden E C; Merritt J A; Robins H I; Steeves R; Bryan G T
Augmented antiproliferative effects of interferons at elevated temperatures against human bladder carcinoma cell lines.
Cancer research 1984;44(12 Pt 1):5517-21.
1984: Borden E C
Progress toward therapeutic application of interferons, 1979-1983.
Cancer 1984;54(11 Suppl):2770-6.
1984: Borden E C; Groveman D S; Nasu T; Reznikoff C; Bryan G T
Antiproliferative activities of interferons against human bladder carcinoma cell lines in vitro.
The Journal of urology 1984;132(4):800-3.
1984: Edwards B S; Hawkins M J; Borden E C
Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Cancer research 1984;44(7):3135-9.
1984: Edwards B S; Merritt J A; Jelen P A; Borden E C
Effects of diethyldithiocarbamate, an inhibitor of interferon antiviral activity, upon human natural killer cells.
Journal of immunology (Baltimore, Md. : 1950) 1984;132(6):2868-75.
1984: Dixon R M; Borden E C; Keim N L; Anderson S; Spennetta T L; Tormey D C; Shrago E
Decreases in serum high-density-lipoprotein cholesterol and total cholesterol resulting from naturally produced and recombinant DNA-derived leukocyte interferons.
Metabolism: clinical and experimental 1984;33(5):400-4.
1984: Hawkins M J; Borden E C; Merritt J A; Edwards B S; Ball L A; Grossbard E; Simon K J
Comparison of the biologic effects of two recombinant human interferons alpha (rA and rD) in humans.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1984;2(3):221-6.
1984: Borden E C; Balkwill F R
Preclinical and clinical studies of interferons and interferon inducers in breast cancer.
Cancer 1984;53(3 Suppl):783-9.
1984: Gould M N; Kakria R C; Olson S; Borden E C
Radiosensitization of human bronchogenic carcinoma cells by interferon beta.
Journal of interferon research 1984;4(1):123-8.
1984: Fuhlbrigge R C; Edwards B S; Borden E C
Effects of interferon alpha on the sheep erythrocyte "receptor" of human lymphocytes.
Journal of interferon research 1984;4(4):499-505.
1984: Willson J K; Bittner G; Borden E C
Antiproliferative activity of human interferons against ovarian cancer cells grown in human tumor stem cell assay.
Journal of interferon research 1984;4(4):441-7.
1983: Lerner H J; Schoenfeld D A; Martin A; Falkson G; Borden E
Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience.
Cancer 1983;52(11):1981-5.
1983: Earhart R H; Koeller J M; Davis T E; Borden E C; McGovren J P; Davis H L; Tormey D C
Phase I trial and pharmacokinetics of acivicin administered by 72-hour infusion.
Cancer treatment reports 1983;67(7-8):683-92.
1983: Busse W W; Swenson C A; Borden E C; Treuhaft M W; Dick E C
Effect of influenza A virus on leukocyte histamine release.
The Journal of allergy and clinical immunology 1983;71(4):382-8.
1983: Edwards B S; Hawkins M J; Borden E C
Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Journal of biological response modifiers 1983;2(5):409-17.
1983: Groveman D S; Borden E C
In vitro and in vivo effects of levamisole on monocyte chemotaxis in normal donors and patients with colorectal carcinoma.
Journal of biological response modifiers 1983;2(2):167-74.
1983: Hogan T F; Padgett B L; Walker D L; Borden E C; Frias Z
Survey of human polyomavirus (JCV, BKV) infections in 139 patients with lung cancer, breast cancer, melanoma, or lymphoma.
Progress in clinical and biological research 1983;105():311-24.
1983: Borden E C
Interferons and cancer: how the promise is being kept.
Interferon 1983;5():43-83.
1983: Borden E C
Interferons: in pursuit of the promise.
Progress in clinical and biological research 1983;132E():287-96.
1982: Borden E C; Hogan T F; Voelkel J G
Comparative antiproliferative activity in vitro of natural interferons alpha and beta for diploid and transformed human cells.
Cancer research 1982;42(12):4948-53.
1982: Liberati M; Borden E C; McBain J A; Raubertas R
Effects of levamisole on human natural killer and killer cell activity and production of interferons.
Immunopharmacology 1982;5(1):11-8.
1982: Borden E C; Ash A; Enterline H T; Rosenbaum C; Laucius J F; Paul A R; Falkson G; Lerner H
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas.
American journal of clinical oncology 1982;5(4):417-20.
1982: Borden E C; Holland J F; Dao T L; Gutterman J U; Wiener L; Chang Y C; Patel J
Leukocyte-derived interferon (alpha) in human breast carcinoma. The American Cancer Society phase II trial.
Annals of internal medicine 1982;97(1):1-6.
1982: Liberati A M; Voelkel J G; Borden E C; Coates A S; Citrin D L; Bryan G T
Influence of non-specific immunologic factors on prognosis in advanced bronchogenic carcinoma.
Cancer immunology, immunotherapy : CII 1982;13(2):140-4.
1982: Edwards B S; Borden E C; Smith-Zaremba K
Divergence in activation by poly I:C of human natural killer and killer cells.
Cancer immunology, immunotherapy : CII 1982;13(3):158-63.
1981: Mischler N E; Tormey D C; Klotz J; Borden E C; Ramirez G; Banerjee T K; Carr R M; Zaentz S D; Graf J
Phase II study of dibromodulcitol in colorectal, kidney, and other carcinomas.
Cancer clinical trials 1981;4(4):407-10.
1981: Borden E C; McBain J A; Martin J; Walker D
Augmentation in the infectivity of SV40 virus DNA by amphotericin B methyl ester: brief report.
Archives of virology 1981;69(2):161-5.
1981: Borden E C
Cellular modulation of induction by polyribonucleotides of interferons.
Texas reports on biology and medicine 1981;41():122-8.
1981: Borden E C; Ball L A
Interferons: biochemical, cell growth inhibitory, and immunological effects.
Progress in hematology 1981;12():299-339.
1980: Borden E C; Hawkins M J
Interferons for human neoplastic and viral diseases.
Comprehensive therapy 1980;6(10):6-15.
1980: Esposito J J; Palmer E L; Borden E C; Harrison A K; Obijeski J F; Murphy F A
Studies on the poxvirus Cotia.
The Journal of general virology 1980;47(1):37-46.
1980: Hogan T F; Borden E C; McBain J A; Padgett B L; Walker D L
Human polyomavirus infections with JC virus and BK virus in renal transplant patients.
Annals of internal medicine 1980;92(3):373-8.
1980: Hogan T F; Padgett B L; Walker D L; Borden E C; McBain J A
Rapid detection and identification of JC virus and BK virus in human urine by using immunofluorescence microscopy.
Journal of clinical microbiology 1980;11(2):178-83.
1979: Borden E C
Interferons: rationale for clinical trials in neoplastic disease.
Annals of internal medicine 1979;91(3):472-9.
1979: Borden E C; McBain J A; Leonhardt P H
Effects of amphotericin B and its methyl ester on the antiviral activity of polyinosinic:polycytidylic acid.
Antimicrobial agents and chemotherapy 1979;16(2):203-9.
1979: Zarling J M; Eskra L; Borden E C; Horoszewicz J; Carter W A
Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon.
Journal of immunology (Baltimore, Md. : 1950) 1979;123(1):63-70.
1979: Borden E C; Booth B W; McBain J A
Enhancement of infectivity of encephalomyocarditis virus RNA by amphotericin B methyl ester.
The Journal of general virology 1979;42(2):297-303.
1978: Hogan T F; Citrin D L; Johnson B M; Nakamura S; Davis T E; Borden E C
o,p'-DDD (mitotane) therapy of adrenal cortical carcinoma: observations on drug dosage, toxicity, and steroid replacement.
Cancer 1978;42(5):2177-81.
1978: Zarling J M; Sosman J; Eskra L; Borden E C; Horoszewicz J S; Carter W A
Enhancement of T cell cytotoxic responses by purified human fibroblast interferon.
Journal of immunology (Baltimore, Md. : 1950) 1978;121(5):2002-4.
1978: Booth B W; Borden E C
Increase by calcium in production of interferon by L929 cells induced with polyriboinosinate-polyribocytidylate complex.
The Journal of general virology 1978;40(2):485-8.
1978: Borden E C
Synergistic cytotoxicity for L929 cells of polyriboinosinic-polyribocytidylic acid and amphotericin B methyl ester.
Journal of the National Cancer Institute 1978;60(6):1309-11.
1978: Borden E C; Booth B W; Leonhardt P H
Mechanistic studies of polyene enhancement of interferon production by polyriboinosinic-polyribocytidylic acid.
Antimicrobial agents and chemotherapy 1978;13(2):159-64.
1977: Borden E C; Leonhardt P H
Aquanititave semimicro, semiautomated colorimetric assay for interferon.
The Journal of laboratory and clinical medicine 1977;89(5):1036-42.
1977: Borden E C; Larson P; Ansfield F J; Bryan G T; Johnson R O; Ramirez G; Wilson W L
Hexamethylmelamine treatment of sarcomas and lymphomas.
Medical and pediatric oncology 1977;3(4):401-6.
1976: Ansfield F J; Davis H L; Ramirez G; Davis T E; Borden E C; Johnson R O; Bryan G T
Further clinical studies with megestrol acetate in advanced breast cancer.
Cancer 1976;38(1):53-5.
1976: Borden E C; Leonhardt P H
Enhancement of rIn:rCn-induced interferon production by amphotericin B.
Antimicrobial agents and chemotherapy 1976;9(3):551-3.
1975: Ansfield F J; Ramirez G; Davis H L; Wirtanen G W; Johnson R O; Bryan G T; Manalo F B; Borden E C; Davis T E; Esmili M
Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil.
Cancer 1975;36(6 Suppl):2413-7.
1975: Borden E C; Prochownik E V; Carter W A
The interferon refractory state. II. Biological characterization of a refractoriness-inducing protein.
Journal of immunology (Baltimore, Md. : 1950) 1975;114(2 pt 2):752-6.
1974: Borden E C; Carter W A; Sensenbrenner L L; Owens A H; Lichtenstein J; Gray G D; Neil G L; Nichol F R; Li L H
Inhibition by streptovaricins of Rauscher leukemia virus splenomegaly.
International journal of cancer. Journal international du cancer 1974;14(6):817-25.
1974: Borden E C; Nathanson N
Tacaribe virus infection of the mouse: an immunopathologic disease model.
Laboratory investigation; a journal of technical methods and pathology 1974;30(4):465-73.
1974: Borden E C; Baker E R; Abeloff M D
Symposium on breast cancer. Introduction.
The Johns Hopkins medical journal 1974;134(2):65.
1974: Borden E C
Viruses and breast cancer: implications of mouse and human studies.
The Johns Hopkins medical journal 1974;134(2):66-76.
1972: Borden E C; Carter W A
Viral chemotherapy: its promise and problems.
Medicine 1972;51(3):189-90.
1972: Carter W A; Pitha P; Brockman W W; Borden E C; Marshall L W
Selective inhibition of viral functions: the antiviral action of interferon and streptovaricin.
Medicine 1972;51(3):181-8.
1971: Murphy F A; Borden E C; Shope R E; Harrison A
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Electron microscopic studies.
The Journal of general virology 1971;13(2):273-88.
1971: Borden E C; Shope R E; Murphy F A
Physicochemical and morphological relationships of some arthropod-borne viruses to bluetongue virus--a new taxonomic group. Physiocochemical and serological studies.
The Journal of general virology 1971;13(2):261-71.
1971: Borden E C; Brockman W W; Carter W A
Selective inhibition by streptovaricin of splenomegaly induced Rauscher leukaemia by virus.
Nature: New biology 1971;232(33):214-6.
1971: Carter W A; Brockman W W; Borden E C
Streptovaricins inhibit focus formation by MSV (MLV) complex.
Nature: New biology 1971;232(33):212-4.
1971: Monath T P; Borden E C
Effects of thorotrast on humoral antibody, viral multiplication, and interferon during infection with St. Louis encephalitis virus in mice.
The Journal of infectious diseases 1971;123(3):297-300.
1971: Borden E C; Murphy F A
The interferon refractory state: in vivo and in vitro studies of its mechanism.
Journal of immunology (Baltimore, Md. : 1950) 1971;106(1):134-42.
1970: Borden E C; Gary G W; Murphy F A
Comparison of agar and agarose preparations for mengovirus plaque formation.
Applied microbiology 1970;20(2):289-91.
1970: Borden E C; Murphy F A; Gary G W
Attempted suppression of the interferon response in the mouse.
Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.) 1970;134(3):865-9.
1969: Borden E C; Murphy F A
Depression of interferon production after A.L.S. treatment.
Lancet 1969;2(7633):1307-8.
1969: Borden E C; Holling H E
Hypertrophic osteoarthropathy and pregnancy.
Annals of internal medicine 1969;71(3):577-80.
1968: Borden E C; Rostand S G
Recovery from massive amitriptyline overdosage.
Lancet 1968;1(7554):1256.
1967: Borden E C
John Locke, physician and author of the first Carolina Constitution.
Southern medical journal 1967;60(3):283-8.

Sign-in to see more